Our investigational oral antiviral COVID-19 medicine

In collaboration with Ridgeback Biotherapeutics, we advanced our research and development efforts for our investigational oral antiviral COVID-19 medicine. We continue to make a meaningful impact with this important tool for physicians, patients and the health care system.

We're working with health authorities to make our oral antiviral treatment available globally.

Our commitment to access

We have a long track record of making our medicines and vaccines accessible and affordable. Our comprehensive supply and access strategy has enabled timely and broad access to our investigational oral antiviral COVID-19 medicine to patients around the world, including in low- and middle-income countries.  

Our approach includes purchase and supply agreements with the governments of several countries worldwide. Additionally, we signed voluntary license agreements with multiple generic manufacturers and the Medicines Patent Pool to help make generic versions of our treatment option available to more than 100 low- and middle-income countries. We’ve also allocated up to 3 million courses of therapy to UNICEF for low- and middle-income countries.

Through our licensing agreements with generics manufacturers and the Medicines Patent Pool, more than 5 million courses of generic therapy have been delivered to 22 low- and middle-income markets included in the licenses through December 2022. 

Clinical trials

We continue our research efforts to study our oral antiviral medicine in other infectious diseases.